The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: Preliminary results

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 65-68

  Lee, Yoo Young ^a   Choi, Chel Hun ^a   Kim, Chul Jung ^a   Kang, Heeseok ^a   Kim, Tae Joong ^a   Lee, Jeong Won ^a   Lee, Je Ho ^a   Bae, Duk Soo ^a   Kim, Byoung Gie ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Early cervical cancer; Oncology; PET; Prognostic factor; Recurrence; SUVmax

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DRUG UPTAKE; EARLY CANCER; FEMALE; HUMAN; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RADICAL HYSTERECTOMY; RECURRENCE RISK; RECURRENT CANCER; REFERENCE VALUE; UTERINE CERVIX CANCER;

CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 69249222588     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.022     Document Type: Article

References (21)

1. Berek J.S. In: Berek JS. (Ed). Berek and Novak's Gynecology. 14th edition (2007) 1426
2. Kostakoglu L., and Goldsmith S.J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J. Nucl. Med. 44 (2003) 224-239
3. Allal A.S., Slosman D.O., Kebdani T., Allaoua M., Lehmann W., and Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 1295-1300
4. Downey R.J., Akhurst T., Gonen M., Vincent A., Bains M.S., Larson S., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J. Clin. Oncol. 22 (2004) 3255-3260
5. Sasaki R., Komaki R., Macapinlac H., Erasmus J., Allen P., Forster K., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 1136-1143
6. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., De Leyn P.R., Verbeken E.K., Deneffe G.J., et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J. Clin. Oncol. 17 (1999) 3201-3206
7. Kidd E.A., Siegel B.A., Dehdashti F., and Grigsby P.W. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110 (2007) 1738-1744
8. Xue F., Lin L.L., Dehdashti F., Miller T.R., Siegel B.A., and Grigsby P.W. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol. Oncol. 101 (2006) 147-151
9. Kieninger A.N., Welsh R., Bendick P.J., Zelenock G., and Chmielewski G.W. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am. J. Surg. 191 (2006) 433-436
10. Lin C., Itti E., Haioun C., Petegnief Y., Luciani A., Dupuis J., et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J. Nucl. Med. 48 (2007) 1626-1632
11. Schwartz D.L., Rajendran J., Yueh B., Coltrera M.D., Leblanc M., Eary J., et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch. Otolaryngol. Head Neck Surg. 130 (2004) 1361-1367
12. Seo S., Hatano E., Higashi T., Nakajima A., Nakamoto Y., Tada M., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 143 (2008) 769-777
13. Liao C.T., Chang J.T., Wang H.M., Ng S.H., Hsueh C., Lee L.Y., et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int. J. Radiat. Oncol. Biol. Phys. 73 (2009) 764-771
14. Burri R.J., Rangaswamy B., Kostakoglu L., Hoch B., Genden E.M., Som P.M., et al. Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008) 682-688
15. Higashi K., Ito K., Hiramatsu Y., Ishikawa T., Sakuma T., Matsunari I., et al. Yamamoto I. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J. Nucl. Med. 46 (2005) 267-273
16. Li M., Liu N., Hu M., Shi F., Yuan S., Zhang P., et al. Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer. Lung Cancer 63 (2009) 383-386
17. de Geus-Oei L.F., van der Heijden H.F., Corstens F.H., and Oyen W.J. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 110 (2007) 1654-1664
18. Keyes Jr. J.W. SUV: standard uptake or silly useless value?. J. Nucl. Med. 36 (1995) 1836-1839
19. Weber W.A., Schwaiger M., and Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl. Med. Biol. 27 (2000) 683-687
20. Weber W.A., Ziegler S.I., Thodtmann R., Hanauske A.R., and Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J. Nucl. Med. 40 (1999) 1771-1777
21. Nahmias C., and Wahl L.M. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J. Nucl. Med. 49 (2008) 1804-1808